Bladder Cancer - Invasive Urothelial Bladder Cancer 
Bone Cancer - Osteosarcoma / chondrosarcoma / rare subtypes 
Breast Cancer - Subtype defined by an amplification of the HER2 gene 
Breast Cancer - Ductal carcinoma 
Pediatric Brain Tumors - Medulloblasma & Pediatric Pilocytic Astrocytoma 
Brain Cancer - Pediatric Medulloblastoma 
Oral Cancer - Gingivobuccal 
Chronic Lymphocytic Leukemia - CLL with mutated and unmutated IgVH 
Liver Cancer - Hepatocellular carcinoma (Virus associated) 
Ovarian Cancer - Serous cystadenocarcinoma 
Rare Pancreatic Tumors - Enteropancreatic endocrine tumors and rare pancreatic exocrine tumors 
Gastric Cancer - Intestinal- and diffuse-type 
; 
| France: | Assistance Publique - Hôpitaux de Paris (AP-HP) |
| Centre de Ressource National Biologique des Tumeurs Hépatiques | |
| CHU de Bordeaux | |
| Institut National du Cancer (INCa) |
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and it is the third most common cause of cancer mortality. Different risk factors that promote the development of chronic hepatitis, cirrhosis and then HCC include viral etiologies through hepatitis B (HBV) or C (HCV) infection or exposure to Aflatoxin B1 (AFB1); alcohol intake and metabolic syndrome are also major risk factors, alone or in combination with viral infections, particularly in France. Recent comprehensive analysis of large number of genetic and epigenetic alterations together with transcriptome and systematic pathway analyses enabled to identify the HCC diversity, description that is essential toward the definition of a molecular classification. However, the identification of efficient tools for early detection of HCC and innovative targeted-drugs is a major issue that needs the development of new accurate biomarkers.
Eight liver centres in France have joined their effort to collect, preserve and distribute tissue samples from hepatocellular carcinomas, according to the recommendations for Biological Resources Centres (BRC) released by the Organisation for Economic Cooperation and Development (OECD), which were recently implemented in France. This led to the creation of a Liver cancer biobanks network which is recognized by the Ministry of research and the Ministry of health and sponsored by the main research agencies, namely Inserm and INCa. Samples are collected and stored locally, whereas related annotations are remotely collected within a central database. The management of the network includes a Scientific Committee, an Executive Board and an Epidemiology and Management Coordinating Centre. http://chc.isped.u-bordeaux2.fr/
| France: | Centre National de Génotypage (CNG) |
| Institut National de la Santé et de la Recherche Médicale (INSERM) |
Whole genome sequencing (Illumina).
| France: | Fondation Synergie Lyon Cancer |
| Institut National de la Santé et de la Recherche Médicale (INSERM) |
Genomic analyses including SNP-CGH, Transcriptome analyses and miRNA profilling.
| France: | Centre National de Génotypage (CNG) |
The aim of the project is to identify a catalog of somatic gene mutations and rearrangements in HCC related to alcohol and metabolic syndrome. As a first step, we will perform a pilot study with a whole genome sequencing of 14 HCC and their corresponding non-tumor liver samples. The mutated genes will be further validated in a series of 500 HCC from the Centre de Ressource National Biologique des tumeurs hépatiques.
• Fabien Calvo
• Jessica Zucman-Rossi
• Mark Lathrop